These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18827790)

  • 1. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
    Zeidan A; Wang ES; Wetzler M
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):673-83. PubMed ID: 18827790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
    Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
    Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
    Stein B; Smith BD
    Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
    Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
    J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies in controlling drug resistance.
    Frame D
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
    Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
    J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
    Jabbour E; Cortes JE; Kantarjian HM
    Mayo Clin Proc; 2009 Feb; 84(2):161-9. PubMed ID: 19181650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of response to imatinib: mechanisms and management.
    Shah NP
    Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Kujawski L; Talpaz M
    Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
    Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.